What the research found

Researchers identified a specific gut bacterium (Bacteroides uniformis) that appears protective against atherosclerosis development. When administered to mice genetically prone to rapid plaque buildup on a high-fat diet, the bacterium slowed—but did not reverse—arterial damage over 12 weeks, performing comparably to atorvastatin, a standard statin drug.

The mechanism hinges on a fatty acid the bacterium produces called pentadecanoic acid (C15:0). This molecule triggers liver cells to ramp up their LDL receptors (the machinery that pulls "bad" cholesterol out of the blood) by creating a chemical signal that mimics low cholesterol availability. C15:0 achieves this by directly inhibiting HMG-CoA reductase, the same enzyme that statin drugs target, though it does so less potently. In people with high blood lipids, C15:0 levels were noticeably lower than in healthy controls, and genetic markers for C15:0-producing bacteria were less common in those with atherosclerotic disease.

Why it matters for you

If you're tracking lipid panels (LDL, HDL, triglycerides) as part of your protocol, this points to a potential adjunct strategy: deliberately cultivating Bacteroides uniformis or supplementing its metabolite. The appeal is mechanistic clarity—you'd know exactly which bacterial strain and which molecule are at work, rather than relying on broad-spectrum prebiotic or probiotic approaches. Some MyKine users already experiment with targeted bacterial strains; this gives one candidate a credible rationale.

That said, the effect was modest compared to statin therapy. C15:0 reduced plaque burden by roughly 50% in mice, whereas atorvastatin performed "noticeably better." For users currently on statins or with significant cardiovascular risk, this probably isn't a replacement. For those with borderline lipids or those looking to optimize beyond pharmaceutical intervention, it might warrant attention—though human evidence doesn't exist yet.

C15:0 is already available as a supplement (branded as "Endoboost" or similar). However, buying the isolated fatty acid is not equivalent to colonizing your gut with the bacterium itself. The bacterial strain might have additional benefits the molecule alone doesn't capture, or the chronic, low-level production from living microbes might have different pharmacokinetics than oral dosing.

Caveats

• Animal model only: All efficacy data come from genetically modified mice. Translation to humans remains uncertain.
• No reversal demonstrated: The treatment slowed progression, not reversed existing plaques—a meaningful distinction for clinical utility.
• Baseline not measured: Comparison was to end-of-study vehicle controls, not pre-treatment values, limiting interpretation of true effect size.
• Weaker than standard therapy: C15:0 inhibited the target enzyme less potently than atorvastatin and produced smaller atherosclerosis reduction.
• Human data minimal: Observational association only (lower C15:0 in people with dyslipidemia and atherosclerotic disease). No intervention trial exists.
• Long-term safety unknown: No data on sustained C15:0 supplementation or B. uniformis colonization in humans.